The stock was trading with minor gains at the opening time and hit the day s high of Rs 1,430.45 on the NSE, up 0.84% over the Wednesday closing price.
Sun Pharmaceutical Industries reported a 17.4% YoY growth in net profit for Q4, beating estimates. Consolidated revenue grew 10% YoY. The company recommended an interim dividend payout. EBITDA rose 16% YoY and margins expanded. Raw material cost fell, but staff cost increased. India formulation sales and US formulation sales grew, while emerging markets formulation sales declined.
Sun Pharmaceutical Industries is set to release its Q3 results, with expected moderate earnings growth. Analysts will monitor factors including US business growth, Taro Pharmaceutical s performance, margin trajectory, planned product launches, and R&D investments. Estimated growth in net profit, revenue, and operating profit is also anticipated. The company is expected to see a rise in US revenue, driven by specialty sales. Growth in domestic formulations is projected, and R&D spend will be closely monitored.
​Sun Pharma on Wednesday reported a 16.5% year-on-year (YoY) jump in net profit to Rs 2524 crore in Q3FY24 led by broad-based growth, including higher sales of global specialty products.
Sun Pharmaceutical Industries Ltd is expected to report single-digit revenue growth for Q3 earnings, with moderate sales in the US and India. Analysts predict a nearly 8% YoY growth in consolidated net profit to Rs 2,329 crore. Consolidated revenue is estimated to rise 9% YoY to Rs 12,265.40 crore.